FeesSafety
Pluang+

Verastem's cancer drug sales hit $25.1M in Q2 '26; key trial data expected in October

Market News
06 Oct 2026, 11:31 WIB
Seeking Alpha
View Source
Bullish
Verastem's cancer drug sales hit $25.1M in Q2 '26; key trial data expected in October

Verastem Inc. reported $25.1 million in net product revenues for Q2 2026 from its Avmapki Fakzynja Co-pack, used for certain ovarian cancer patients. The company is also developing a KRAS G12D inhibitor, VS-7375, targeting multiple cancers, with important clinical trial results from the TARGET-D 101 study expected in October. This upcoming data readout represents a significant near-term catalyst for the company. Additionally, GenFleet Therapeutics, also developing VS-7375, will provide updated data in the same timeframe, highlighting ongoing progress in this cancer treatment area.

Verastem's upcoming clinical readout and commercial launch are noted here with Pluang's health sector data as of Oct 06, 2026 14:12 WIB. Of 100 priced health-sector US stocks tradable on Pluang, 69 rose and 27 fell today. Notable movers include ADMA Biologics Inc at USD 10.10 with a 3.91% increase and a typical hold time of 17 days, Stryker Corporation at USD 285.17 up 3.54%, and Cassava Sciences Inc at USD 0.90 rising 3.46%, with Pluang order activity heavily favoring selling for ADMA and Stryker but buying for Cassava Sciences.

More News

Warren Buffett's bet reveals stocks outperform bonds long-term, delivering $2M vs $1M from Treasury bonds.

Warren Buffett's bet reveals stocks outperform bonds long-term, delivering $2M vs $1M from Treasury bonds.

Warren Buffett's 10-year $1 million bet showed that professional money managers couldn't beat the S&P 500, and his experience with zero-coupon U.S. Treasury bonds revealed their risks. Midway through the bet, Buffett shifted from low-yield bonds to B...

Market News
Bullish
1 hour ago
Coca-Cola offers steady dividend growth but requires $560K for $1,000 monthly income amid high valuation.

Coca-Cola offers steady dividend growth but requires $560K for $1,000 monthly income amid high valuation.

Coca-Cola, a Dividend King with 64 years of consecutive dividend increases, currently pays $2.12 annually per share, yielding about 2.15%. To earn $1,000 monthly in dividends, an investor would need to buy approximately 5,661 shares, costing around $...

Market News
Bullish
1 hour ago
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and showing improved health markers. This success could lead to lab...

Company Fundamentals
Bullish
1 hour ago
Mercury Systems raises revenue outlook with record $2B backlog and $370M Q1 bookings

Mercury Systems raises revenue outlook with record $2B backlog and $370M Q1 bookings

Mercury Systems reported a record backlog exceeding $2 billion and first-quarter bookings of $370 million, up 48% year-over-year, driven by a shift from low-margin development contracts to higher-volume production orders. The company has paid down $2...

Company Fundamentals
Bullish
1 hour ago
Red Cat Holdings withdraws 2026 revenue target amid defense contract delays and restructures aerial division.

Red Cat Holdings withdraws 2026 revenue target amid defense contract delays and restructures aerial division.

Red Cat Holdings has withdrawn its full-year 2026 revenue target due to delays in defense contract awards and missed milestones in military drone competitions. The company has built up $127 million in inventory to prepare for future orders and restru...

Company Fundamentals
Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App